

IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE

THE RESEARCH FOUNDATION OF
STATE UNIVERSITY OF NEW YORK;
NEW YORK UNIVERSITY; GALDERMA
LABORATORIES INC.; AND GALDERMA
LABORATORIES, L.P.,

Plaintiffs,

v.

MYLAN PHARMACEUTICALS INC.

Defendant.

C.A. No. 09-184 (LPS)

MYLAN PHARMACEUTICALS INC.,

Plaintiff,

v.

GALDERMA LABORATORIES INC.,
GALDERMA LABORATORIES, L.P., and
SUPERNUS PHARMACEUTICALS, INC.,

Defendants.

C.A. No. 10-892 (LPS)

JOINT ERRATA FOR TRIAL TRANSCRIPTS

POTTER ANDERSON & CORROON LLP
Richard L. Horwitz (# 2246)
David E. Moore (# 3983)
Hercules Plaza, 6th Floor
1313 N. Market Street
Wilmington, DE 19801
Tel: (302) 984-6000
rhorwitz@potteranderson.com
dmoore@potteranderson.com

Attorneys for Mylan Pharmaceuticals Inc.

MORRIS, NICHOLS, ARSHT & TUNNELL LLP
Jack B. Blumenfeld (# 1014)
Maryellen Noreika (# 3208)
1201 North Market Street
P.O. Box 1347
Wilmington, DE 19899-1347
(302) 658-9200
jblumenfeld@mnat.com
mnoreika@mnat.com

*Attorneys for The Research Foundation of
State University of New York, New York
University, Galderma Laboratories Inc.,
Galderma Laboratories, L.P., Galderma
Laboratories Inc., Galderma Laboratories,
L.P. and Supernus Pharmaceuticals, Inc.*

OF COUNSEL:

David S. Steuer
Matthew R. Reed
WILSON SONSINI GOODRICH & ROSATI
650 Page Mill Road
Palo Alto, CA 94394-1050
(650) 493-9300

July 20, 2011

OF COUNSEL:

Gerald J. Flattmann, Jr.
Christine Willgoos
PAUL, HASTINGS, JANOFSKY & WALKER LLP
75 East 55th Street
New York, NY 10022
(212) 318-6000

*Research Foundation of State University of New York, et al. v. Mylan
Pharmaceuticals, Inc.*
Case No. 09-184-LPS
Mylan Pharmaceuticals, Inc. v. Galderma Labs., et al.
Case No. 10-892-LPS

Parties' Joint Errata for Trial Transcripts dated 7/5/2011 to 7/8/2011

Page:Line	Errata	Correction
1:16	Monday	Tuesday
6:14	Dr. Redding's	Dr. Rudnic's
6:15	Dr. Reddy's	Dr. Rudnic's
10:12	between	behind
11:8	treated	created
13:23	supposed	supposedly
14:1	CollaGenex's	CollaGenex
18:13	use	used
19:9	Toltan	Talton
21:12	themes	these
23:2	take	teach
24:8	But	But the
25:1	interrogatory	interrogatories
25:7	much of	of
26:25	never a	never
29:20	wouldn't	won't
30:1	that in	that are in
31:11	Maybe	Much less
31:12	formulations	portions
34:11	doesn't	don't
34:19	in amounts	in claimed amounts
34:23	nitro oxide or inducible nitro	nitric oxide or inducible nitric
35:19	nitro	nitric
35:25	dropped it	dropped its
36:1	obviousness	obviousness defense
36:11	in d	in
36:25	problem	public
37:14	crying	clear
37:21	rosacea	Oracea
71:22	immune system	innate immune system
71:25	native	innate
72:3	Galderma	Gallo
72:20	rosacea	Oracea
73:14	wide	white
75:15	diary	diarrhea
76:17	suspect	the same
77:12	augur	agar
77:20	M C	MIC
83:1	drug	row
85:19	an	and
86:20	condition	section

Page:Line	Errata	Correction
90:13	equities	effects
93:10	date	data
93:11	PTX-314	PTX-413
98:5	in vivo to in vivo	in vitro to in vivo
99:24	prosecution	percent
101:15	it	that
103:4	phases	states
105:20	to	do
107:21	duration	calculation
109:9	in	and
110:19	30	40
111:17	10	40
111:18	sub-bacterial	sub-antibacterial
114:14	early	little
115:9	Oracea	references
128:21	not	nothing
132:1	rosacea	Oracea
138:22	PTX-2322	DTX 2322
143:7	disclosure	exposure
145:25	sample	sampled
146:3	statistical	statistically
147:16	flabella	glabella
147:20	flabella	glabella
151:10	much	of
154:10	flabella	glabella
156:19	stand	stands
162:5	Helibactora	Helicobacter
164:18	non-bacterial static concentration	non-bacteriostatic concentrations
171:21	What	When
172:15	Monopharmaceutics	Modern Pharmaceutics
177:11	product	products
181:20	Covans (phonetic)	Covance
186:10	or	of
192:9	Do you	Q. Do you
193:8	patents	patent
193:18	relation	system
196:8	'829	'819
201:10	each	teach
204:9	peritonitis	periodontitis
207:25	Lens of a	lens of the
216:5	PTX-50	PTX-530
216:8	PTX-50	PTX-530
224:11	Carbitol	Carbatrol
226:22	them	that
228:1	that you tell	that tell you
229:10	SythesPharma	Scintipharma
231:5	doxycycline two to	doxycycline in two to
231:17	secreted	excreted
231:19	secretion	excretion
234:11	Oracea	ratio

Page:Line	Errata	Correction
245:15	Carbitol	Carbatrol
246:13	Carbitol	Carbatrol
262:3	of	for
262:3	in	and
267:15	WOOD	REED
268:3	affects	effects
268:23	Bruch Gerhars	Bruch-Gerharz
269:12	WOOD	REED
269:22	pathogenetic (occurs twice)	pathogenic
270:2	leucocyte	leukocyte
270:13	leucocytes	leukocytes
270:19	Shulman	Schöllmann
270:23	Yamazaki	Yamasaki
270:24	Gallow	Gallo
270:24	Molecular Car Pathology	Molecular Pathology
271:8	disregulated	dysregulated
272:6	Rosacea,	Rosacea:
272:14	WOOD	REED
273:2	develop	development
274:9	WOOD	REED
274:23	extravagation	extravasation
275:7	disregulated	dysregulated
275:8	ions	iNOS
276:7	up regulation	upregulation
276:16	ion	iNOS
277:6	iso-enzyme	enzyme
278:9	ions	iNOS
279:23	3.2	322
280:24	up regulation	upregulation
281:18	macrophage	macrophages
282:7	in	and
287:21	Oracea	rosacea
288:10	Oracea	rosacea
288:15	product in	product, in
288:16	Oracea	rosacea
297:10	pathogenetic	pathogenic
301:14	WOOD	REED
301:18	WOOD	REED
301:24	WOOD	REED
304:22	WOOD	REED
305:2	WOOD	REED
305:3	WOOD	REED
318:3	up-regulatable	upregulated
318:7	up-regulatable	upregulated
321:2	in end	and in
329:12	WOOD	REED
329:15	WOOD	REED
331:9	WOOD	REED
331:13	WOOD	REED
331:23	WOOD	REED

Page:Line	Errata	Correction
340:20	she	he
361:12	now	not
374:16	Tuesday	Wednesday
376:24	WOOD	REED
377:8	WOOD	REED
384:6	Wood	Reed
384:11	WOOD	REED
384:24	Walters-Kluwer	Wolters Kluwer
385:16	WOOD	REED
386:3	WOOD	REED
386:10	WOOD	REED
386:23	WOOD	REED
388:18	WOOD	REED
388:24	WOOD	REED
389:7	WOOD	REED
390:1	WOOD	REED
390:9	WOOD	REED
390:12	WOOD	REED
390:15	WOOD	REED
390:16	briefs	pages
390:24	WOOD	REED
400:16	ever	ever call up
404:9	eight	ate
412:15	prepared this slide	prepared slides
413:9	of	for
413:16	did	do
413:25	hold	have
414:2	author	authored
414:23	focussed	focused
418:6	Carrie	Karrie
419:21	of	[remove "of"]
425:10	indigent	integer
428:15	dermatalgic	dermatologic
433:12	showings	shows
440:6	prescription March	prescription in March
449:15	name	[remove "name"]
453:18	independent	dependent
453:20	specifically	specific
455:6	decade	decades
455:8	does	doses
459:3	infringes is	infringes if
464:12	hydrate	hyclate
464:20	tat	that
464:23	dermatalgic	dermatologic
464:25	of	or
465:6	conferred	converted
466:11	as well the	as well as the
474:23	possessing	possess
478:21	pilus	pilo
479:15	we treated	retrieved
479:15	pilus	pilo

Page:Line	Errata	Correction
479:20	pilus	pilo
480:8	1970	1970s
483:1	pilus	pilo
490:24	other	another
492:11	dermatalgic	dermatologic
492:15	ophthalmalgic	ophthalmologic
492:15	ocular	ocular
494:8	objection see	oxy
494:8	thugs	thus
495:21	the that	the claims that
496:9	at	of
498:6	Oracea	rosacea
503:7	Corre3vct	Correct
503:17	HIPPA	HIPAA
503:20	HIPPA	HIPAA
518:14	not	now
522:23	didn't	did
527:12	h pylori	H. pylori
529:18	does	dose
539:18	730	732
548:9	Harry	Henry
561:7	studied	funded
572:14	in case	indicate
575:15	Walker study	Walker 2000 study
611:9	hours, it's	hours. It's
611:10	per mil. For the	per mil for the
628:19	1524	154
630:10	cites	sites
640:17	and	at
640:18	administration at	administration and
648:23	cites	sites
656:13	no9t	not
663:18	millimeter	milliliter
680:1	etched	evidence
681:20	millimeter	milliliter
682:11	millimeter	milliliter
683:6	millimeter	milliliter
685:2	millimeter	milliliter
685:7	millimeter	milliliter
685:23	millimeter	milliliter
687:1	millimeter	milliliter
687:11	millimeter	milliliter
687:19	millimeter	milliliter
689:18	millimeter	milliliter
695:5	Bruch-Gerhars	Bruch-Gerharz
698:20	Shulman	Schöllmann
699:12	Bruch Gerhars	Bruch-Gerharz
699:14	Bruch Gerhars	Bruch-Gerharz
715:22	Chang patent	Amin patents
720:19	millimeter	milliliter
720:21	millimeter	milliliter

Page:Line	Errata	Correction
722:9	millimeter	milliliter
722:9	access	x axis
723:16	not	in
725:7	coating	coding
726:22	leucocyte	leukocyte
730:10	Thelma	Bouwsma
751:10	starting	start up
751:18	Spark	SPARK
751:20	The purpose of the Spark program is to lead as	The purpose of the SPARK program is to link up
752:2	appear	a peer
752:5	appearing	peer reviewing
752:15	KK2	Caco-2
756:9	Partitioner	A practitioner
760:14	be valid	invalid
761:23	Mohlberg	Malmborg
765:4	simulistic plot	semilog plot
766:13	primer	parameters
766:19	credit size	criticize
776:7	millimeter	milliliter
776:21	millimeter	milliliter
776:22	millimeter	milliliter
780:14	Mylan	Elan
781:14	microcytes.	microbicides.
782:9	witness binder thee at	witness binder at
782:22	expert in the designing	expert in the field of designing
785:4	claimed of 0.1	claimed of 0.3
786:3	below low a	below a
786:13	SODIS and IPDOS.	SODAS and IPDAS.
796:4	ratio of ranges	range of ratios
800:17	a dependent	an independent
800:22	times of acne.	forms of acne.
806:21	do is it	does it
813:24	millimeter	milliliter
814:17	millimeter	milliliter
814:24	millimeter	milliliter
834:3	millimeter	milliliter
834:4	millimeter	milliliter
858:25	millimeter	milliliter
860:1	millimeter	milliliter
864:17	WESTIN	GILL
864:17	Karen	Kirin
865:9	under	understand
868:1	session	says
868:9	companions	compositions
869:10	inconveniencing	invention
878:12	I was	is
897:15	millimeter	milliliter
897:16	millimeter	milliliter
899:22	millimeter	milliliter

Page:Line	Errata	Correction
908:15	chose	choose
915:15	millimeter	milliliter
919:5	millimeter	milliliter
919:8	mid release	immediate-release
919:14	millimeter	milliliter
928:8	millimeter	milliliter
928:9	millimeter	milliliter
945:14	millimeter	milliliter
945:18	millimeter	milliliter
953:5	millimeter	milliliter
953:6	millimeter	milliliter
976:12	were	are
977:1	concentrations	concentration
978:7	asserted	contested
979:23	taught that both	taught both
980:14	that have	when they would have
981:18	Mylan	Mylan's
981:19-20	limitation claim	claim limitation
981:23	the reducing	reducing the
982:12	doxycycline per day or	doxycycline or
982:15	use an anti-infection	use in an infection
983:22	He	It
985:18	antibody tissue	body tissues
987:10	are	are the result of
989:19	above	about
991:20	file	pile
992:15	that doesn't	doesn't
992:16	bacteria flora or bacteria flora	bacterial flora or bacterial flora
999:25	patents	references
1000:25	tact	tactic
1001:4	creditably	credibly
1003:18	the idea	an idea
1004:19	okay	"okay"
1005:10	immediate-release,	immediate-release and
1006:8	dose	doses
1009:1	oxide in	oxide synthase in
1010:7	His own	Mylan's own
1011:11	rosacea	Oracea
1012:12	that particular	that any particular